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Abstract
Interstitial lung disease (ILD) events have been reported in Japanese non-small-cell lung cancer (NSCLC) patients receiving
EGFR tyrosine kinase inhibitors. We investigated proteomic biomarkers for mechanistic insights and improved prediction of
ILD. Blood plasma was collected from 43 gefitinib-treated NSCLC patients developing acute ILD (confirmed by blinded
diagnostic review) and 123 randomly selected controls in a nested case-control study within a pharmacoepidemiological
cohort study in Japan. We generated ,7 million tandem mass spectrometry (MS/MS) measurements with extensive quality
control and validation, producing one of the largest proteomic lung cancer datasets to date, incorporating rigorous study
design, phenotype definition, and evaluation of sample processing. After alignment, scaling, and measurement batch
adjustment, we identified 41 peptide peaks representing 29 proteins best predicting ILD. Multivariate peptide, protein, and
pathway modeling achieved ILD prediction comparable to previously identified clinical variables; combining the two
provided some improvement. The acute phase response pathway was strongly represented (17 of 29 proteins,
p=1.0610
225), suggesting a key role with potential utility as a marker for increased risk of acute ILD events. Validation by
Western blotting showed correlation for identified proteins, confirming that robust results can be generated from an MS/MS
platform implementing strict quality control.
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Introduction
Interstitial lung disease (ILD) affects the pulmonary parenchyma
or alveolar region [1]. When associated with drug treatment, it can
present precipitously as acute diffuse alveolar damage (DAD),
sometimes with a fatal outcome [2]. Patients often have severe
breathlessness and chest radiology shows ‘ground glass’ appear-
ance. No specific treatment is available, but supportive therapy
includes oxygen, corticosteroids, or assisted ventilation. Acute ILD
events may develop de novo, but an existing chronic ILD condition
increases the risk considerably [3], as observed in recent studies of
patients with idiopathic pulmonary fibrosis (IPF), the most
common chronic form [4].
ILD, especially IPF, is a known co-morbidity in patients with
non-small-cell lung cancer (NSCLC) [5]. Acute ILD events have
been reported with many lung cancer therapies at rates up to
,10% [6–11]. ILD is recognized as more common in Japan than
elsewhere, both in the population and among patients with
NSCLC [5,6,12,13], although it is unclear why.
EGFR tyrosine kinase inhibitors (TKIs) are an established
treatment for advanced NSCLC. Unlike much chemotherapy,
they are typically well tolerated and without cytotoxic side effects.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22062The EGFR TKI gefitinib (IRESSA) was approved in 2002 in
Japan for treatment of advanced NSCLC. Although some ILD-
type events were observed in clinical trials and compassionate
clinical use, only after approval did an increasing number of
spontaneous reports for ILD appear in Japan as the drug became
more widely available.
At that point, better understanding of ILD was urgently needed:
baseline incidence on different treatments, risk factors, and the
potential association of gefitinib with ILD risk. An independent
academic team together with AstraZeneca scientists therefore
designed and conducted a cohort and nested case-control
pharmacoepidemiological study of ILD in Japanese NSCLC
patients treated with either gefitinib or chemotherapy, with clinical
results reported previously [3]. As one exploratory sub-study
component, patients receiving gefitinib (both subsequent ILD
cases and control patients) were sampled for plasma proteomics,
with two main objectives: 1) to identify proteomic predictors of
ILD that might ultimately be developed into a personalized
medicine diagnostic to identify patients at greater risk of ILD; 2) to
increase understanding of the mechanisms underlying the
development of acute ILD events.
Using a multiple biomarker approach such as proteomics (the
simultaneous study of large parts of the human proteome to give a
global view of differential expression of proteins in blood or tissue),
rather than simply a conventional single biomarker, potentially
increases predictive power both through increased robustness
deriving from multiple measurements and the opportunity to
combine information from multiple biological processes. To
support high-quality generation of such information, we combined
in a novel way several key study components: robust study design,
well-defined phenotypic definitions, careful sample collection
procedures, stable advanced liquid chromatography (LC)-tandem
mass spectrometry (MS/MS)-based peptide separation and
detection methods, statistical analysis incorporating proteomic
and clinical information, stringent methods for database protein
annotation of detected peptide peaks, and biological interpretation
using literature mining software, plus extensive quality control and
validation, reported below.
Results
Characteristics of the study population
The non-randomized cohort included 3,166 Japanese patients
with advanced/recurrent NSCLC who were followed for 12 weeks
after initiating gefitinib (n=1,872 treatment periods) or chemo-
therapy (n=2,551). From the gefitinib-treated sub-cohort, 103
suspected ILD cases (79 subsequently confirmed and 24 rejected
by the Case Review Board [CRB]), as well as 252 controls, were
registered into the case-control study. Proteomics samples for this
sub-study were available from 43 confirmed ILD cases, 123
control subjects, and 15 CRB-rejected initially diagnosed ILD
cases (Table 1). Clinical characteristics of the cases and controls
are described in Table S1.
Exploratory analysis of LC-MS/MS data generated under
quality controlled conditions reveals large batch
variation that needs to be controlled in subsequent
statistical analyses
Quality assessment of sample processing and data
generation. After immunoaffinity depletion, remaining serum
albumin was ,8% for all 181 baseline samples (Table S2). The
subsequent tryptic hydrolysis resulted in a remaining undigested
protein portion ranging from 3.0% to 32.3% (mean 15.3%) (Table
S2). The variation in these processing steps was independent of
case/control status (data not shown).
LC-MS/MS measurements for the 181 individual baseline
samples were performed in 11 batches, with 19 and 20 samples
from batches 1 and 3 repeated in batches 10 and 11, respectively
(Table 1), resulting in 220 discrete proteomics measurements. Four
of the 11 batches initially failed the quality control criteria
(coefficient of variation [CoV] .20% for any one of the six control
Table 1. Composition of the LC-MS/MS measurement batches for 181 blood plasma samples from Japanese patients with NSCLC.
Batch number
Number of study
samples not analyzed
in previous batches
Number of analyzed
samples
a Type of study subject
ILD case Control Rejected case
b
1 20 20 3 15 2
2 20 20 5 13 2
3 20 20 6 12 2
4 20 20 3 15 2
5 20 20 6 12 2
6 20 20 5 14 1
7 20 20 6 13 1
8 20 20 3 16 1
9 20 20 6 12 2
10
c 1
c 20
c 31 5 2
11
c 0
d 20
d 61 2 2
Total 181 220 52 (43
e) 149 (123
e) 19 (15
e)
aEach batch also contained 3 experimental control samples in positions 1, 12, and 23 of total batch size of 23.
bCase Review Board (see Materials and Methods) did not confirm clinical ILD diagnosis after blinded diagnostic review.
c19 samples from batch 1 repeated, 1 new control analyzed.
dAll 20 samples from batch 3 repeated.
eNumber of unique study subjects.
doi:10.1371/journal.pone.0022062.t001
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measurement run, but passed the criteria on repeated measure-
ment. A quality control summary of acceptable batch runs is given
in Figure 1A.
Figure 1B shows a plot of partial correlations between the
duplicate samples in batches 1 and 10, 3 and 11, after allowing for
any batch effect, against the average normalized intensity over the
complete sample set for each signal. Peptides with higher average
intensities show higher reproducibility between batches as
evidenced by generally high partial correlations.
Exploratory data analysis of MS signal intensities. We
then used a principal component analysis (PCA) to explore the
data in order to identify the largest sources of variation. Figure 2A
shows a plot of this analysis, with each sample colored according to
batch. Measurements from the same batch tend to cluster
together, separate from other batches, implying that the largest
differences between samples arise from the batch-wise processing.
Figure 2B shows the results of PCA on the pairs of repeated
batches (1 and 10, 3 and 11), with duplicate samples joined by a
line, plotted against the first two principal components. The lines
are generally horizontal and parallel, again suggesting that the
largest source of variability or the greatest overall differences in
profiles between samples (first principal component) relates to
inter-batch variability, and that the ordering of samples on the
second principal component, i.e. in the next largest source of
variability or overall differences between samples, is in strong
agreement between the repeated batches. After allowing for
consistent differences between batches, these results thus confirm
that inter-sample differences are reproducible with the method
used.
Whereas Figure 2B compares results summarized over all
measured peptides, Figure 2C shows the repeated run results for
an example peptide. Although there are large between-batch
differences, within each batch there is high correlation between the
intensities for the same subject on replicate runs. Of the 41
differentially expressed peptide peaks used to identify the proteins
listed in Table 2, 25 (61%) show a partial correlation after
removing the batch effect greater than 0.8 and all show a partial
correlation in excess of 0.35.
Clear differences in peptide and protein patterns
between ILD cases and controls
The subsequent analyses aimed to identify peptides and proteins
that effectively discriminatedbetweencasesand controls,sorejected
cases were now excluded. Repeated samples in batches 10 and 11
were excluded, and given the large between-batch differences
identified in the exploratory analyses, the control subject measured
in batch 10 was also excluded, leaving 43 confirmed ILD cases and
122 controls with one sample measurement each.
Identification of discriminating peptides and proteins.
Figure 3 shows the results of the univariate (individual peptide)
analyses using analysis of covariance (ANCOVA), displayed as
histograms of the p-values for the comparison between cases and
controls. Allowing for batch as an analysis covariate, to remove
inter-batch variation, substantially increases the power of the
analysis, identifying approximately twice as many peptides
showing statistically significant differential expression at the 5%
level. Figures S1 and S2 explore and explain this relationship in
more detail. Further accounting for the within-batch order only
slightly decreases the number of significant peptides, suggesting
that any within-batch order effect is marginal and attempts to
model it will not increase power.
On the other hand, allowing for key clinical variables (WHO
performance status [PS], smoking history, extent of normal lung
Figure 1. Quality control: reproducibility of control samples and sample duplicates. (A) Reproducibility of 6 control peaks for the 3
standard quality control samples, plotted as ‘+’, in each analysis batch (peak intensity, left axis). The coefficients of variation (%, right axis) between
the 3 control samples in each batch are plotted as points joined by a line. (B) Reproducibility of peptide intensities for 39 samples with duplicate
analyses in different analysis batches. Partial correlation, after removing between batch differences, plotted against the average normalized intensity
for each peptide. Higher intensity peptides show high reproducibility in their intensities between repeated batches.
doi:10.1371/journal.pone.0022062.g001
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analysis consistently reduced the number of peptides being
detected as differentially expressed, reflecting that much of the
information carried in the most significant peptides is duplicating
information carried by the clinical variables (Figure 3). Figure S3
shows an example of this, where higher levels of the peptide,
higher performance status score and case status are all associated
with each other, and much of the increased peptide intensity of the
cases compared with the controls can be explained by their
association with higher performance status score, so the peptide
intensity is adding much less information when considered in
combination with this clinical variable.
Based on the p-value, the top 100 peaks from both the analyses
including and excluding clinical variables were identified. These
peaks were subsequently restricted to 41 according to the following
criteria: 1) normalized LC retention time between 5 and 75 min,
and 2) full scan m/z value of the precursor ion between 450 and
1,500. Next, peptide identifications included in the 41 peptide
peaks were selected using the following criteria: 1) a Mascot ion
score more than the identity threshold value given to the
individual amino acid sequence of the peptide; and 2) .3 samples
with the corresponding peptide identification. This resulted in 45
valid peptide identifications from 28 of the 41 peaks, including two
peptides from the spiked lysozyme (Table S3). The plasma-derived
43 peptides represented 27 distinct identifications with 2 dual
identifications of closely related proteins, for a total of 29 proteins.
These are listed in Table 2, with more detail concerning their
identification given in Table S3.
Acute phase response identified as an important
pathway likely to be involved in acute ILD events
This set of proteins was then used in the biological
interpretation analyses, using the Ingenuity Pathway Analysis
(IPA) system. The most significant pathway found when overlaying
the proteins onto Ingenuity-curated canonical pathways was the
acute phase response signaling pathway, with which 17 of the 29
proteins could be associated (p=1.0610
225). Other pathways
showing a high overlap with the list of proteins included the
complement and coagulation pathways, but p-values were less
significant due to the smaller number of proteins involved
(Figure 4).
Entering the 29 proteins into IPA, 5 networks were formed. The
most significant network contains 24 of the 29 proteins (Figure 5).
Proteins added to the network by the tool to connect the marker
proteins include IL1 and NF-kB, suggesting that these proteins
could also be involved in generating the observed pattern.
Combining the two networks with the highest scores further adds
IL1-beta, HNF1A, HNF4A, HNF6 (ONECUT1), and CEBPB as
central components (Figure S4).
Validation of the MS/MS data shows good reproducibility
and reasonable agreement with Western blot
Within the MS/MS platform there was strong agreement
between replicate runs of the same samples after allowing for batch
effects, as described above (Figure 2C).
Validating with another method, Table 2 shows the correlation
in intensities derived from the MS/MS and Western blotting (WB)
for a selection of 9 proteins. Considering that WB targets the intact
protein, whereas the present MS/MS can detect peptides derived
from the intact proteins, these 9 proteins show quite a strong level
of agreement between the technologies, with 6 of the 9 proteins
Table 2. List of 29 proteins representing 27 protein
identifications from the 41 selected peaks, with pathway
assignments according to ingenuity analysis and the
validation of ms/ms results using western blots on 12 subjects
(6 ILD cases and 6 controls).
Protein name
Acute Phase
Response
pathway
Correlation
between
expression levels
using MS/MS and
Western blot
alpha-1-acid glycoprotein 1 YES 0.717
alpha-1-antitrypsin YES 0.512
alpha-1B-glycoprotein
Leucine-rich alpha-2-glycoprotein
alpha-1-antichymotrypsin YES 0.744
Antithrombin-III
Apolipoprotein A-I YES 0.468
Apolipoprotein B-100
Apolipoprotein C-III
Armadillo repeat-containing protein 2
Complement C3 YES 0.242
Complement C4-A, Complement C4-B
a,b YES 0.768
Complement component C9 YES
Plasma kallikrein YES
alpha-2-HS-glycoprotein YES 0.808
Gelsolin 0.873
Hemoglobin alpha
Hemoglobin beta, Hemoglobin delta
b
Haptoglobin YES 0.859
Haptoglobin-related protein
Histidine-rich glycoprotein YES
Inter-alpha-trypsin inhibitor heavy chain
H4
YES
Retinol binding protein 4 YES
Serum amyloid P-component YES
Serotransferrin YES
Transthyretin YES
Ig kappa chain V-III region Ti
aC4 beta chain (common to C4A and C4B).
bDual identification of 2 closely related proteins from the same protein family.
doi:10.1371/journal.pone.0022062.t002
Figure 2. Exploratory data analysis of MS signal intensities using PCA. (A) Plot of first two principal components from PCA analysis of the
full proteomic data from all 11 analysis batches (numbered 1–11 in time sequence). Each sample is represented by a single point, with the range of
points within each batch being shown by a polygon joining the extreme points in that batch. (B) Plots of the first two principal components for the
repeated batches of samples (1 and 10, 3 and 11). Individual samples are represented by a line, connecting the two replicates in different batches. (C)
Reproducibility of an example differentially expressed peptide between two duplicate batch runs of proteomic analysis. The intensities of the first
and second runs for each replicated sample are plotted against each other. Samples colored by batch (batch 1 repeated as batch 10 – blue; batch 3,
repeated as batch 11 – red). Allowing for between-sequence differences there is a good correlation between replicate runs.
doi:10.1371/journal.pone.0022062.g002
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the MS/MS and WB protein intensities are shown in Figure S5
and the WB images in Figure S6.
Prediction of ILD using proteins and clinical data
Modeling phenotype based on multiple peptide
markers. Figure 6A shows the predictive power based on
leave-one-out cross-validation for models built using a range of
different numbers of peptides in combination. Substantial
improvements on random prediction were obtained from just a
few peptides, and increasing the number of peptides further did
not substantially improve the model predictions. The predictive
power of the model even decreased when using very many
peptides.
For robustness, alternative multivariate modeling approaches
were compared. Using random forests instead of partial least
squares discriminant analysis (PLS-DA) and logistic regression
within the modeling framework yielded approximately the same
predictive level as evidenced by the area under the curve (details
not shown).
A subgroup analysis restricting the set of cases to those with the
DAD acute ILD pattern (20 of the 43 cases) was hampered by
small sample size and was unable to improve the overall predictive
power.
Modeling phenotype based on multiple peptide markers
and clinical data. Figure 6B compares the predictive power,
based on leave-one-out cross validation, for models built on
clinical/radiological data alone using a logistic regression, peptide
data alone, and a combination. Both data types alone provided
similar prediction. Some improvement was obtained by combining
the two data types, but it was far less than additive. This is
consistent with the results from the analysis of individual peptides,
suggesting that the discriminating peptides partly carry
information also available from the clinical/radiological variables.
Modeling phenotypes based on proteins and clinical
data. Figure 7 shows the p-values for distinguishing cases and
controls obtained from the proteins (i.e. combined constituent
peptide score), all their constituent peptides, and the combined
acute phase pathway intensity measure (i.e. the combined score of
the 16 included constituent proteins). For most proteins, the
estimated protein intensity is more significant than most of the
measured peptide intensities associated with that protein, but only
improves on the significance of the best peptide for a few proteins.
As these results were obtained within the same dataset that was
used to identify and select the constituent peptides, some over-
fitting may be occurring, and the protein expression intensity
incorporating information from many peptides may be a more
robust measure to apply in a wider context. The combined acute
phase pathway intensity measure shows a more significant
response than any of the constituent proteins. A similar picture
is obtained when we consider the additional information provided
by the peptide, protein and pathway measures on top of the known
clinical variables in predicting ILD status (Figure S7).
Figure 8A shows the acute phase response pathway intensity
plotted against a combined clinical variable score measuring the
likelihood of a subject being a case calculated from a logistic
regression of case-control status against the clinical variables
WHO PS, smoking history, extent of normal lung coverage on CT
scan, and severity of pre-existing ILD. This shows both sources of
information contributing to predicting ILD outcome, although
these two measures are fairly strongly correlated, so that much of
the information is duplicated. Figure 8B considers the implications
Figure 3. Distribution of significance tests of differential expression between cases and controls for individual peptides. The figure
shows the effect on the distribution of p-values for differential expression of including analysis processing information and clinical variables.
doi:10.1371/journal.pone.0022062.g003
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istics (ROC) curves for the clinical variables, the acute phase
pathway intensity, and the combination of the two sources of
information. This shows comparable levels of predictive power
from the clinical variables and acute phase pathway intensities,
and some potential benefit from combining them together which,
however, is limited, reflecting their correlation.
Discussion
We present here results from a proteomic analysis applied to a
large-scale pharmacoepidemiological study and demonstrate that
with considerable attention to study design and experimental
procedures throughout the entire process required to generate
high-quality data, it is possible to derive valuable knowledge from
both a scientific and a diagnostic perspective. However, there are
numerous potential sources of data variation and bias in this
process. The integrity of all of the steps of the process is critical to
generating useful data and failure to ensure high quality in any one
of them may compromise the validity and value of the entire study.
Methodological aspects
Study design and sample preparation. We applied careful
phenotyping with blinded diagnostic review to ensure an accurate
ILD diagnosis, and incorporated measures to ensure that all cases
of ILD occurring in the source cohort would be captured. Controls
were selected from the actual population generating the cases,
ensuring comparability between cases and controls so that
contrasts seen may be attributed to case status. Participation
rates were high (.90%) and similar for cases and controls [3],
making selection bias unlikely. Proteomics samples were obtained
after separate informed consent from approximately half of all
gefitinib-treated cases and controls. Steps to ensure high-quality
proteomic data for our large-scale epidemiological investigation
included randomization of the processed samples, careful quality
assessment of sample preparations and optimized preparation
protocols to ensure stability in all procedures for a large number of
samples. We have previously described the general strategy that
we decided to use in the study based on a number of experimental
pilot phase rounds [14].
Experimental measurement batch effects. Two-
dimensional polyacrylamide gel electrophoresis is one common
conventional technology used for protein analysis in serum/
plasma [15,16]. Currently, LC-MS/MS has become widely
accepted for high-resolution proteome-wide profiling from a
complex peptide mixture [17]. Recent advances in this
methodology including improved stability of peptide separation
and detection has enabled comparison of ion intensity between
LC-MS/MS profiles [18]. Our proteomics analysis system applied
LC-MS/MS after immunoaffinity depletion of the most abundant
constituent proteins in blood plasma, and proteolytic enzyme
treatment of the depleted plasma sample.
We identified that the LC-MS/MS measuring process has
systematic measurement errors, as one might expect, which we
took measures to eliminate by introducing batch processing with
quality control, designing the order of sample processing to
Figure 4. Significant associated pathways with ILD status. The most significant pathways from an analysis linking the identified 29 proteins
from the study to curated pathways in the Ingenuity Pathway Analysis system are shown, ordered according to the ratio between the number of
protein markers that can be associated with the pathway and the number of proteins in the pathway.
doi:10.1371/journal.pone.0022062.g004
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22062Figure 5. Highest scoring Ingenuity Pathway Analysis network. Highest scoring network generated from entering the identified 29 proteins
into the Ingenuity Pathway Analysis system, with proteins identified in the study shaded grey and connecting proteins identified by Ingenuity
Pathway Analysis non-shaded. Dark blue shapes and lines = proteins identified as predictors in this study and interactions between them. Grey
shapes and lines = proteins identified by Ingenuity to generate the network and interactions between them. Light blue lines = interactions between
proteins identified by Ingenuity to generate the network and the proteins identified in the study. Figure S4A shows this figure with the interaction
relationships labeled. Proteins identified in the study and included in the network: SERPINA1 = alpha-1-antitrypsin; SERPINA3 = alpha-1-
antichymotrypsin; SERPINC1 = antithrombin-III; APOA1 = apolipoprotein A-I; APOB = apolipoprotein B-100; APOC3 = apolipoprotein C-III; C3 =
complement C3; C4A, C4B = complement C4-A; complement C4-B; C9 = complement component C9; GSN = gelsolin; HBA2 = hemoglobin alpha;
HBB, HBD = hemoglobin beta/delta; HP = haptoglobin; HPR = haptoglobin-related protein; HRG = histidine-rich glycoprotein; KLKB1 = plasma
kallikrein; IGKC = Ig kappa chain V-III region Ti; RBP4, Rbp = retinol binding protein 4; APCS = serum amyloid P-component; TF = serotransferrin;
TTR = transthyretin. Proteins identified in the study and not included in the network: ORM1 = alpha-1-acid glycoprotein 1; A1BG = alpha-1B-
glycoprotein; LRG1 = leucine-rich alpha-2-glycoprotein; ARMC2 = armadillo repeat-containing protein 2; AHSG = alpha-2-HS-glycoprotein; ITIH4 =
inter-alpha-trypsin inhibitor heavy chain H4.
doi:10.1371/journal.pone.0022062.g005
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batch effects in the statistical analysis. The consideration of batch
effects in the statistical analysis appeared to improve the process of
detecting discriminating peaks, and we therefore based our final
protein identification step on this analysis approach.
Alignment algorithms – internal standard-guided
Optimal Profile ALignment (i-OPAL). In order to allow
comparative quantification between samples, the sample
measurements have to be aligned – i.e. the correspondence of
ion signals must be identified. Various methods have been
proposed for this, e.g. based on stable isotope labeling [19–21],
utilizing comparative identification [22,23], or with direct
comparison of the respective peptide ion signals [18]. The i-
OPAL method belongs to the last category. In spite of the
relatively low accuracy and mass resolution of m/z measurement,
the MS instrument of ion-trap type allows a long-term stable
measurement without any calibration operation [24,25].
Consequently, the m/z values are directly comparable in a large
set of samples without further transformations.
Biological findings and implications
Potential biological mechanisms underlying acute ILD
events. In our IPA mapping to canonical biological pathways,
acute phase proteins came out as the strongest signal, followed by
the complement and coagulation pathways. Activation of acute
phase response with connection to the complement and
coagulation systems have been suggested as key processes in
acute ILD events following blood transfusions (transfusion related
acute lung injury; TRALI) [26] and in patients with idiopathic
thrombocytopenic purpura (ITP) [27]. Acute phase responses can
be induced by bronchoscopy with bronchoalveolar lavage [28].
Available evidence strongly suggests that balance between injury
and repair is fundamental for regulating injury repair and
protecting the lung [29]. In our study, clinical findings suggested
that patients had increased risk of acute ILD events early after lung
cancer diagnosis, if they had pre-existing chronic ILD, and if their
remaining normal lung coverage as assessed on CT scan was low
[3], suggesting that factors associated with active or extensive
disease processes and/or cancer diagnostic procedures were
important. Interestingly, another key protein signal (outside the
acute phase pathway) for ILD risk in our study was gelsolin.
Gelsolin was recently highlighted by comparative expression
profiling and animal experiments as necessary for the
development of modeled pulmonary inflammation and fibrosis,
and caspase-3 mediated gelsolin fragmentation was shown to be an
apoptotic effector mechanism and a marker of lung injury, again
emphasizing the balance between injury and repair [30].
Interesting protein connections were also revealed by the IPA-
generated networks. For example, CEBPB (NFIL6) is a principal
effector of cyclin D1 activity in human cancer and an enhancer of
e.g. IL-6 transcription, which plays an important role in the acute
phase response [31,32]. It is important to clarify that IPA-
generated networks are not the same as canonical biological
pathways, but rather connect different proteins and genes based
upon a wide range of interactions reported in the scientific
literature.
Biomarker validation. Within this study we have validated
our conclusions on several different levels. Technical validation by
repeating the analysis of the same samples has confirmed the
ability of the technology to reproducibly measure the levels of the
peptides within the samples. This has been strengthened by the use
of alternative technologies to confirm the intensities of key
proteins. Together, these two sets of validation data show that
the protein intensities derived from this MS/MS analysis are both
reproducible and in agreement with those found from other
technologies. In combination, they provide strong evidence of the
Figure 6. Receiver operating characteristics curve of cross-validated predictions. (A) from peptides, for different number of peptides
included in the proteomic prediction model, and (B) from clinical data, proteomic data, and a combination of both clinical and proteomic data.
doi:10.1371/journal.pone.0022062.g006
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of the results. Biological validation has examined peptides from the
same proteins and identified strong levels of correlation,
strengthening and helping to confirm our hypotheses. Internally,
cross-validation was used as an efficient method for avoiding over-
fitting of a multivariate dataset and estimating an error rate of the
modeling process whilst still maximizing the use of a limited
number of samples. A final level of validation, which has yet to be
addressed in this work, would be to validate our conclusions in a
completely independently collected set of samples. Given the
relative rarity of ILD and the difficult diagnosis, such a dataset
remains to be assembled.
Biomarker properties. The true practical utility of any
molecular diagnostic is not only its ability to make a prediction of
outcome, but also its ability to add additional, alternative, and
more timely information to assist the physician in treating the
patient, at a reasonable cost and effort. With ILD, using clinical
and radiological information which may often be easily available,
a physician is able to make some assessment of the risk of a patient
developing ILD, although this evaluation at present is inexact and
difficult to apply consistently. While a patient’s proteomic profile
appears to provide similar prediction using an alternative method,
and may even improve the accuracy of risk assessment when
added to clinical/radiological information, that improvement is
limited. However, the more objective and possibly more
reproducible character of a proteomic measurement might
provide advantages over a purely clinical assessment. It may also
be noted that the additional value of any component of a risk score
as assessed by ROC change is often very small, as has been
demonstrated for well-known clinical lab tests such as HDL,
HbA1C, and hsCRP in the context of clinically validated
Reynolds Risk Score for cardiovascular disease [33], but that the
individual components contributing to a score or data compilation
used for a clinical decision may nevertheless all contribute to
elevating the combined information above the threshold of clinical
utility. Nevertheless, from both a medical and a commercial
perspective and considering that further validation in independent
sets of patients is still required, as well as development of a
practical, cost-efficient, timely, and clinically available assay, it is
not obvious at this point whether the possible added value justifies
further development of the technology as a potential diagnostic.
Conclusion
This study has identified proteomic markers (peptides) that show
a reasonable predictive power for ILD. However, as might be
expected, the information they carry appears to overlap partly
Figure 7. Significance levels from the proteins, constituent peptides, and acute phase pathway intensities. p-values for the proteins are
shown by red stars, p-values for individual peptides are shown by points, and the distribution of these for each protein is shown by a boxplot. In each
boxplot, the upper and lower sides of the box represent the higher and lower quartile values (Q3 and Q1), respectively. The black bar in each box
represents the median value. The p-value for the acute phase pathway is represented by the dashed line; boxplots for proteins in the acute phase
response pathway are shaded. A1AG1 = alpha-1-acid glycoprotein 1; A1AT = alpha-1-antitrypsin; A1BG = alpha-1B-glycoprotein; A2GL = leucine-
rich alpha-2-glycoprotein; AACT = alpha-1-antichymotrypsin; ANT3 = antithrombin-III; APOA1 = apolipoprotein A-I; APOB = apolipoprotein B-100;
APOC3 = apolipoprotein C-III; ARMC2 = armadillo repeat-containing protein 2; CO3 = complement C3; CO4 = complement C4-A; complement C4-
B; CO9 = complement component C9; FETUA = alpha-2-HS-glycoprotein; GELS = gelsolin; HBA = hemoglobin alpha; HBB, HBD = hemoglobin
beta/delta; HPT = haptoglobin; HPTR = haptoglobin-related protein; HRG = histidine-rich glycoprotein; ITIH4 = inter-alpha-trypsin inhibitor heavy
chain H4; KLKB1 = plasma kallikrein; KV3 = Ig kappa chain V-III region Ti; RETBP = retinol binding protein 4; SAMP = serum amyloid P-component;
TRFE = serotransferrin; TTHY = transthyretin.
doi:10.1371/journal.pone.0022062.g007
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predict ILD, including WHO performance status score, smoking
history, lung coverage on CT scan, and severity of pre-existing
ILD. When combining the two, some gain in predictive power is
obtained, although this is limited based on evaluation by ROC
curves. Basing the predictive model upon the proteins/pathways
identified as interesting shows potential for greater predictive
power. In particular, the data suggest that activated acute phase
response could be a marker for increased risk of acute ILD events
following drug exposure. Whether this is a general mechanism that
may be true also for acute ILD exacerbations in other settings, as
some recent reports would suggest, is an important question for
further research. In any case, our findings again highlight the
potential importance of the balance between destruction and
repair mechanisms for maintaining a functioning lung. If the
results regarding the acute phase pathway can be confirmed, this
may lead to a better mechanistic understanding of the basis for
ILD events occurring, which would have potentially great future
clinical utility as ILD events are an important consideration in the
development of many potent new drugs, particularly in the areas
of respiratory disease and oncology. In addition, such understand-
ing would allow a more targeted approach to identifying and
defining proteomic biomarkers with higher predictive value and
clinical utility than was possible in this exploratory study.
Materials and Methods
Study design – patients and data collection
This non-randomized cohort study with a nested case-control
component was conducted in November 2003 to February 2006 in
50 centers across Japan. Patients with advanced or recurring
NSCLC with at least one previous chemotherapy regimen were
eligible. Patients and their physicians selected a treatment (gefitinib
250 mg or chemotherapy), and follow-up was extended for up to
12 weeks after treatment initiation. Study design has been
described in more detail previously [3]. This proteomics sub-study
was performed only with gefitinib-treated patients from the case-
control study component.
Patients who developed acute ILD during follow-up were
registered to the case-control study nested within the cohort, as
clinically diagnosed potential cases. For each potential case, four
controls were randomly selected from patients then registered to
the cohort who had not developed ILD.
To ensure valid and sensitive ILD diagnosis, the study included
1) an information card describing the symptoms of ILD distributed
to all cohort patients; 2) internationally agreed criteria for ILD
diagnosis and a diagnostic algorithm developed from an
international consensus statement [1]; and 3) an independent
CRB of radiologists and clinicians for blinded diagnostic review of
all clinically diagnosed potential ILD.
For cases and controls, detailed patient data were collected
covering NSCLC treatment, demography, cancer histology,
clinical staging, WHO PS, smoking, previous cancer treatments,
past and current medical history, surgical history, and concomitant
medication and therapy. For gefitinib-treated cohort members
consenting to the proteomics sub-study, one baseline 6-mL
sodium-heparinized blood sample was drawn immediately (1–
3 h) after the first gefitinib dose at registration into the cohort.
Samples were spun for 10 min at 3,000 rpm and the plasma was
stored at –80uC.
Figure 8. Plots illustrating the relationship between acute phase response pathway intensity score and clinical variable score. (A)
Plot of the acute phase response intensity against the combined clinical variable score measuring the likelihood of a subject being a case calculated
from a model predicting case-control status based only on the clinical variables WHO PS, smoking history, extent of normal lung coverage on CT scan,
and severity of pre-existing ILD, with boxplots comparing the distribution of these measures in cases and controls. In each boxplot, the upper/right
and lower/left sides of the box represent the higher and lower quartile values (Q3 and Q1), respectively. The black bar in each box represents the
median value. (B) Receiver operating characteristics curve of cross-validated predictions from clinical data, the acute phase response intensity and a
combination of the clinical data and acute phase response intensity.
doi:10.1371/journal.pone.0022062.g008
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Institutional Review Board of each site approved the study and
informed consent forms. Written informed consent was required
for registration to the study cohort, and separately for registration
to the case-control study and for participation in the proteomics
study.
Sample and data processing
The study was performed with quality control procedures at
each sample processing, data generation, and data processing step,
as described below.
Immunoaffinity depletion of serum albumin and IgG
from the blood plasma and tryptic hydrolysis of plasma
proteins. Depletion of the blood plasma samples was carried
out using a dual Albumin and IgG Removal Kit (GE Healthcare
UK Ltd, Amersham Place, Buckinghamshire, UK) according to
the manufacturer’s instructions, with some modifications. An
affinity resin of a single production lot was used for the depletion
process throughout this investigation. The depletion procedure for
the 181 baseline samples was carried out in 18 batches (Table S1).
As an experimental control, pooled human plasma (Sigma-Aldrich
Inc., St. Louis, MO, USA) was simultaneously subjected to the
same experimental procedures. Prior to the depletion the small
debris part of the biofluid was removed by filtration. Aliquots
(70 mL) of the plasma solution were diluted with 4.0 mL of the
suspended gel slurry containing slurry beads with immobilized
protein G binding polyclonal antibodies against both human
serum albumin and IgG [34]. The sample was incubated on a
rotator (5 rpm, 30 min, room temperature) to keep the gel slurry
in suspension. Subsequently, the serum albumin/IgG-binding
slurry beads were removed from the sample solution by
centrifugation (7,0006g, 5 min) using a Vivaspin 6 column with
polyethersulfone membrane (pore size 0.2 mm; Sartorius AG,
Goettingen, Germany). The recovered liquid fraction
(approximately 3.3 mL), containing unbound plasma proteins,
was subjected to a buffer-exchanging process as follows: the
fraction was condensed on a 3,000 molecular weight cutoff
membrane of polyethersulfone in a diafiltration vessel (Vivaspin 2
column, Sartorius AG, Goettingen), followed by dilution with
excess volume (2 mL) of 50 mM ammonium bicarbonate. This
cycle was repeated three times. Finally the resulting solution was
condensed to less than 100 mL on the same membrane and
adjusted to 200 mL with 50 mM ammonium bicarbonate. The
total protein concentration of the depleted solution was measured
according to Lowry et al [35], using a DC protein assay kit (Bio-
Rad Laboratories Inc., Hercules, CA, USA) with bovine serum
albumin as the calibration standard. To confirm the depletion
treatment, the concentration of the human serum albumin
remaining in the depleted protein solution was measured as
follows: An aliquot of the depleted solution was subjected to
sodium dodecylsulfate (SDS) polyacrylamide gel electrophoresis
(PAGE) [36]. Protein bands on the polyacrylamide gel were
stained with a SYPRO Ruby fluorescence dye (Invitrogen Co.,
Carlsbad, CA, USA), followed by scanning of the gel slab on a
LAS-3000 imaging system (FUJIFILM Co., Tokyo, Japan). Finally
the fluorescence intensity ratio of the serum albumin band to the
all protein bands detected on the gel lane was calculated using a
Multi Gauge image analyzing software (FUJIFILM). The samples
were then stored at –80uC until use.
Tryptic hydrolysis of the plasma proteins. The hydrolysis
procedures were carried out in a single batch (Table S1). An
aliquot containing 200 mg of the depleted plasma sample was
spiked with 250 pmol of egg white lysozyme (Sigma-Aldrich Inc.,
St Louis, MO, USA) used as a source of exogenous internal
standard peptides. Next the samples were denatured by incubating
by gentle agitation in 200 mL of 100 mM ammonium bicarbonate
containing 25% (v/v) acetonitrile at 37uC for 60 min. The
resulting solution was immediately subjected to reductive S-
carboxyamidomethylation of the sulfhydryl groups of the cysteine
residues: incubation by gentle agitation at 37uC for 45 min with
addition of 1 mmol of Tris(2-carboxyethyl)phosphine (TCEP)
(20 mL of 50 mM solution), followed by the addition of 5 mmol
of iodoacetamide (20 mL of 250 mM solution) at room
temperature for 60 min in the dark. The Cys-modified proteins
were further subjected to tryptic hydrolysis by the addition of 4 mg
of porcine trypsin (20 mL of 0.2 mg/mL solution) (Promega Co.,
Madison, WI, USA) and incubation at 37uC for 16 h. The
resulting peptide mixture was stored at –80uC until use.
To measure the degree of hydrolysis, aliquots of the sample
solutions before and after the hydrolysis treatment were subjected
to SDS PAGE [36], followed by obtaining a fluorescence gel
image as described in the previous section. The total fluorescence
intensities of the protein bands were compared between both
solutions to calculate the protein portion remaining due to
incompleteness of the hydrolysis.
LC-MS/MS measurement procedures. The peptide
mixture was then dissolved in 1.0% v/v trifluoroacetic acid
(TFA) aqueous solution with the final peptide concentration of
0.1 mg/mL, and analyzed using an LC-MS/MS system with a
Finnigan LTQ linear ion trap mass spectrometer (Thermo Fisher
Scientific Inc., Waltham, MA, USA) [25] in a fully automated
manner. Briefly, peptide separation was performed with a
Paradigm MS4 LC instrument (Michrom BioResources Inc.,
Auburn, CA, USA) containing a MAGIC C18 capillary LC
column (0.2 mm id, 50 mm length, 3 mm particle size, and 200 A ˚
pore size; Michrom BioResources). The mobile phase consisted of
formic acid, acetonitrile, and water at a volume ratio of 0.1:2:98
for mobile phase A, and 0.1:90:10 for mobile phase B. The initial
flow of 100 mL/min was reduced by a flow splitter to
approximately 1 mL/min. 10 mL of the peptide solution,
containing 1 mg peptide, was applied using an HTS PAL
autoinjector (CTC Analytics AG, Zwingen, Switzerland) onto a
Peptide CapTrap column (0.5 mm id, 2.0 mm length, bed volume
0.5 mL; Michrom BioResources) equilibrated with a solution of
TFA, acetonitrile, and water at a volume ratio of 0.1:2:98. The
peptides concentrated and purified on the trap column were
injected onto the C18 capillary LC column by valve switching. The
peptides were continuously eluted at a rate of 1 mL/min on a
gradient mode: The initial ratio of 5% of mobile phase B was
increased linearly to 40% B during 70 min, followed by the
increase to 95% B during the next 5 min. After washing with a
non-gradient flow at 95% B, the column was equilibrated again
with the solvent of 5% B for the next separation. The total analysis
time was 90 min. For gasification of the protonated peptides, the
LC effluent was interfaced with an electrospray ionization (ESI)
source in a positive ion mode, on a Finnigan LTQ linear ion trap
mass spectrometer (Thermo Fisher Scientific) [25]. The ESI used a
FortisTip spray emitter (20 mm id, top Teflon-coated; AMR Inc.,
Tokyo, Japan) directly connected with the outlet of the LC
column. The set parameters included a spray voltage of 2.0 kV
and a capillary temperature of 200uC. No sheath gas was supplied
during the ESI. The other parameters on the ion separation and
detection were optimized according to an Autotune function in the
mass spectrometer instrument. For MS/MS, protonated peptides
in a gas phase were sequentially analyzed by data-dependent
scanning mode of a full scan at an m/z range of 450 to 2,000 and
subsequent product ion scans of the three most intense precursor
ions. The data acquisitions were made in a Centroid mode for
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including an intensity threshold of 1610
3, 30% normalized
collision energy, 2.0 Da isolation m/z width, and dynamic
exclusion for 30 sec. The ESI-MS/MS operation and data
acquisition were carried out on an Xcalibur Revision 1.4 SR1
system controller (Thermo Fisher Scientific).
The LC-MS/MS measurement was continuously performed
with alternate injection of the sample solutions and blank solutions
for system washing. A single continuous LC-MS/MS measure-
ment batch comprised 23 samples; 20 peptide solutions from
patients and 3 experimental control samples of pooled plasma at
the initial, middle, and final positions. The analysis order of
patient samples was randomized across and within batches, whilst
ensuring reasonable balance between batches in case/control
status (Table 1).
Measurement variability of the ion intensity within each analysis
batch was assessed as the CoV between the three control samples
for the relative ion signal area of each of 6 selected common
peptides, i.e. the ratio of the total signal area of the differently
charged ions shown in Table 3, to the signal area of the most
stably detected internal standard peptide (IS1) derived from the
spiked lysozyme (Table 3).
Signal normalization, signal alignment, and peak
detection in the LC-MS data. Two-dimensional profile data
consisting of LC retention time and full MS scan (LC-MS data)
were extracted from all 220 LC-MS/MS measurements (Table 1)
and processed using the i-OPAL algorithm (Patent # WO/2004/
09526 AI).
i-OPAL is a dynamic programming algorithm that maximizes
the alignment between LC-MS profiles through shrinking or
extending the retention time axis to maximize the similarity in
peak shapes within the chromatograms, and the similarity of the
mass spectra, using a wider range of criteria than alternative data
processing methods including dynamic time warping (DTW) [37]
or correlation optimized warping (COW) [37,38].
An important feature of the i-OPAL algorithm is its utilization
of internal standards, which are forced to be aligned. This reduces
the linear programming problem from the whole range of
retention time to a series of small time sections, increasing the
accuracy of alignment and reducing the computational time.
The i-OPAL program thus consists of 3 parts: 1) signal intensity
normalization using one or more internal standards; 2) alignment
of LC-MS data using internal standard signal sets and a dynamic
programming algorithm; and 3) peak detection. First, the intensity
of the whole signal was normalized across all samples using IS1.
Second, alignment of the three internal standard signal sets
(Table 3) was forced across the LC-MS data. Alignment of the
remaining regions was carried out based on the dynamic
programming algorithm. Following signal alignment, peak detec-
tion was performed using an iterative process.
A clear benefit of i-OPAL relative to other signal alignment
approaches [39] is that peak detection is carried out after
alignment rather than before. Most peak detection algorithms
utilize the shape of peaks, making the integration of weak signals
difficult. Aligning prior to peak detection increases the likelihood
of detection of a peak across the range of samples, which can
increase the numbers of peaks confidently detected.
Statistical analysis and modeling of peptide data
First, Variance Scaling Normalization [40] was applied to the
peaks to scale the signal intensities from each sample to a common
level and also remove any dependency between the mean and
variance of the intensities. PCA [41] of the scaled data was used
for exploratory data analysis to identify the main sources of
variation within the proteomic data.
The analysis to identify single peptide markers associated with
case status then proceeded using ANCOVA, testing significance
using type III sums of squares for each peptide separately, with
normalized peptide intensity as the response and case/control
status as the explanatory variable, with adjustment for some or all
Table 3. Peptides used as internal standards and for assessment of the ion intensity variations across the LC-MS/MS measurement
batches.
Amino acid sequence (From – To)
a Protein name
Retention
time, min
b Ion m/z value
c (charge)
Swiss-Prot
d
accession
number
Peptides for assessment of the ion intensity variations
EGTC
ePEAPTDEC
eKPVK (347–362) Transferrin 10.8–16.6 910.0 (2+), 607.0 (3+) P02787
LRTEGDGVYTLNNEK (117–131) Haptoglobin 19.8–25.2 1,709.9 (1+), 855.4 (2+), 570.6 (3+) P00738
AVGDKLPEC
eEADDGC
ePKPPEIAHGYVEHSVR (78–108) Haptoglobin 27.7–32.5 1,717.9 (2+), 1145.6 (3+), 859.5 (4+) P00738
DYVSQFEGSALGK (52–64) Apolipoprotein A–I 38.0–45.0 1,401.5 (1+), 701.3 (2+) P02647
HSTIFENLANKADRDQYELLC
eLDNTR (226–251) Transferrin 47.8–53.7 1,569.7 (2+), 1046.8 (3+), 785.4 (4+) P02787
TSESGELHGLTTEEEFVEGIYKVEIDTK (69–96) Transthyretin 58.7–66.0 1,571.7 (2+), 1048.1 (3+), 786.4 (4+) P02766
Internal standard (IS) peptides, two exogenous and one endogenous
IS1 FESNFNTQATNR (52–63) Lysozyme 19.562.0 714.862.4 (2+) P00698
IS2 NTDGSTDYGILQINSR (64–79) Lysozyme 36.262.0 877.462.4 (2+) P00698
IS3 ITPNLAEFAFSLYR (50–63) alpha-1-Antitrypsin 67.962.0 821.562.4 (2+) P01009
aResidue numbers in the unprocessed precursor.
bMaximum range for all the analysis batches.
cTolerance of 60.5 m/z unit for the peak area calculation.
d(http://expasy.org/sprot/).
eS-Carboxyamidomethyl cysteine residue.
doi:10.1371/journal.pone.0022062.t003
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within batch (both identified in the PCA), and the statistically
significant clinical and radiological variables most predictive of
ILD identified from the main study, i.e. WHO PS, smoking
history, extent of normal lung coverage on CT scan and severity of
pre-existing ILD [3]. Peptides were then ranked by the significance
of the case-control status term.
To identify and evaluate the best set of peptide predictors,
predictive multivariate modeling was then performed in two steps.
First the n most significant peptides were selected and a PLS-DA
[42] was performed to identify linear combinations of peptides
correlating best with case-control status. This was followed by
logistic regression modeling with case-control status as the
response using the m first PLS components (linear combinations
identified) as predictors. To explore the modeling space, the
number of peptides, n, and the number of PLS components, m,
utilized in the model were varied.
The performance of the statistical analysis and predictive
multivariate modeling was assessed using a leave-one-out cross-
validation approach to estimate sensitivity, specificity, and overall
error rate of the modeling process [43], as follows:
N For each subject in turn, remove this subject as the test set,
considering the remaining subjects as the training set.
N Perform the three steps of statistical analysis (ANCOVA and
multivariate modeling by PLS-DA and logistic regression) as
described above on the training set.
N Use the logistic regression model in the third step to predict the
case-control status of the left-out subject based on the other
data.
N Repeat, omitting each subject in turn from the training set and
predicting the left-out subject and then combining the results
to generate a vector of leave-one-out predictions, one for each
subject, which can be used to give an estimate of the sensitivity
and specificity as well as the overall error rate of the modeling
process.
As a robustness check, Random Forests [44] were also used as
an alternative to the combination of PLS-DA and logistic
regression.
To allow a visualization of the potential choices for the
appropriate levels of sensitivity and specificity, the cross-validated
results are presented as ROC by varying the probability threshold
used for predicting each subject as a case or a control.
Peptide and protein identification
Product ion spectra with at least 10 product ions were converted
into peak lists, which were searched with the Mascot algorithm
[45] against a Swiss-Prot amino acid sequence database. First mass
chromatogram files were generated for every LC-MS/MS
measurement. The subsequent data conversion and search process
was carried out using Mascot software (Version 2.1.04, Matrix
Science Ltd, London, UK). Prior to database search, each product
ion spectrum in these files was converted into peak list(s) using an
extract_msn.exe program (Thermo Fisher Scientific) without any
grouping process. The criterion for the data conversion was at
least 10 product ions in a spectrum. These peak lists were searched
with the Mascot algorithm (MS/MS Ion Search mode) [45]
against a Swiss-Prot amino acid sequence database (http://www.
expasy.org/sprot/; Release 55.0; 18,610 entries (Homo sapiens);
updated on February 26, 2008). The database search parameters
were set as follows: tryptic digestion (hydrolysis of the peptide
bonds following lysine and arginine residues); fixed modification of
cysteine residues (S-carboxyamidomethylation, +57.0 Da); variable
modification of methionine residues (oxidation, +16.0 Da); #2
missed cleavages, i.e. assuming at most 2 predicted tryptic
digestion sites are not actually digested; peptide tolerance of 2.0
Da; an MS/MS tolerance of 60.8 Da (http://www.matrixscience.
com).
Bioinformatics
Identification of significant pathways. We utilized the
IPA system (IngenuityH Systems, www.ingenuity.com) to analyze
the set of proteins we identified as demonstrating a significant
difference in expression levels between cases and controls. The
Ingenuity Pathways Analysis Knowledge Base is a large curated
database of previously published findings on mammalian biology.
The version used was v. 6.5, build 59570, content version 1602,
build oqa-kb_enif, 2008-08-20, 21:16:03.
The list of proteins identified was overlaid onto the curated
pathways in IPA. The dynamic Canonical Pathways are well-
characterized metabolic and cell signaling pathways that have
been curated and hand-drawn. The information contained in
Canonical Pathways comes from specific journal articles, review
articles, text books, and the KEGG (Kyoto Encyclopedia of Genes
and Genomes) ligand database (http://www.genome.jp/kegg/
ligand.html). The most significant pathway was identified as the
pathway with the highest network score. The network score is
based on the hypergeometric distribution and is calculated with
the right-tailed Fisher’s Exact Test. The score is the negative
logarithm of this p-value. The ratio for an overlay to a given
pathway was calculated by the ratio between the number of
proteins from the data set found in the pathway and the total
number of proteins associated to the pathway.
Gene network analysis. Gene network analysis was
performed using IPA Systems web-based software application
(http://www.ingenuity.com/products/pathways_analysis.html). In
this approach the Ingenuity literature data are used to identify
interconnected protein networks based on reported interactions
identifying particular proteins as interacting with each other.
Protein level modeling
For each of the proteins identified (through one or more
peptides) as having the greatest significant difference between cases
and controls, the full set of digested peptides from that protein was
also identified, and a summary protein intensity (using the
intensities of all component peptides) was calculated using a
method based on PCA, as follows:
1. Remove the batch effect from all the peptide intensities by
subtracting the batch means.
2. Restrict the set of peptides to those with a positive correlation
after removing the batch effect with the peptide showing the
greatest evidence of differential expression between the case
and control groups (i.e. the smallest p-value).
3. Arrange the remaining batch adjusted peptide intensities in a
matrix and apply PCA on the scaled data matrix.
4. The score of the first principal component, i.e. the greatest
source of variability, is the protein intensity score.
Where there is strong correlation between all the constituent
peptides, this method will produce effectively an average of the
peptide intensities, as the loadings given to all the peptides will be
similar. Where a peptide has low correlation with the remaining
peptides, either because it is also a digestion product and therefore
measuring other proteins, or has low intensity making it an
unreliable measurement, then it will receive a low loading in the
PCA and will contribute little to the protein intensity measure.
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intensities of proteins within a common pathway in a similar
manner by taking the scores from the first principal component of
the matrix of protein intensities.
Protein and pathway intensities were modeled using logistic
regression, with case-control status as the response and optionally
the clinical variables as predictive variables, in an analogous way
to peptide intensities as described above.
Validation
Reproducibility of the identified differentially expressed pep-
tides was validated by comparing the peptide intensities from 39
repeated samples with duplicate MS/MS analysis, allowing for
consistent between-batch differences.
To validate between technologies, protein intensities derived
from MS/MS were compared with those derived from Western
blots with densitometry for 9 key selected proteins identified by
the statistical and bioinformatic analyses. The depleted plasma
proteins were reduced and denatured in the presence of 50 mM
dithiothreitol and 2% w/v SDS at 95uC for 5 min, and then
subjected to SDS-PAGE with 7.5%, 10%, or 12% acrylamide
(0.1 or 1 mgp r o t e i nper lane). Separated proteins were electrically
transferred onto polyvinylidene difluoride (PVDF) membranes
(Bio-Rad Laboratories) with a wet-type transfer system. After
transfer, non-specific binding reactions were blocked by rocking
the membranes for 1 h with 3% w/v BSA and 3% w/v
polyvinylpyrrolidone K30 in TBST (150 mM NaCl, 0.05% v/v
Tween 20 and 10 mM Tris-HCl, pH 8.0). The membranes were
then washed with TBST, incubated with antibodies in TBST
containing 0.1% BSA (TBST-BSA) for 30 min, washed again
with TBST, and finally incubated with a HRP-conjugated second
antibody in TBST-BSA for 30 min (Table S4). After washing
again with TBST, the specific binding was detected using an
ECL-Plus system (GE Healthcare) according to the manufactur-
er’s instructions, in combination with a LAS-3000 imaging
analyzer (FUJI FILM). For densitometry, the gel image was
opened with Image-J software (National Institutes of Health,
Research Services Branch, USA; http://rsbweb.nih.gov/), and
the density of each band was obtained. After subtraction of a
background value, the density data were used for further
analyses.
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Figure S1 Comparison of p-values for all detected
peptides from analyses adjusted for and unadjusted
for batch. All peptides showing a significant difference in the
unadjusted analysis also show a significant difference in the
analysis adjusted for batch. The analysis adjusted for batch also
identifies additional significantly differentially expressed peptides
that were not detected by the unadjusted analysis.
(TIF)
Figure S2 Effect of batch-to-batch variability on the
overall intensity difference between cases and controls
for peptides. (A) An example peptide which exhibits no
discernable between-batch variation and so is significant
independent of whether the analysis is adjusted for batch or
not. (B) An example peptide with a highly significant variation
between batches, which consequently is only significant when
batch is accounted for. Overall pooled effect not adjusting for
batch on left, followed by batches 1–9 with one study sample each
from 180 of the 181 study subjects. Red = cases; blue =
controls.
(TIF)
Figure S3 Effect of adjusting for key clinical variables.
Left panel shows a comparison of p-values for all detected peptides
from analyses adjusted for and unadjusted for 4 key clinical
variables. Right panel shows an example of the effect of
accounting for the clinical variable WHO PS on the pattern of
intensity difference between cases and controls. Overall pooled
effect on left, followed by case-control difference (red = cases;
blue = controls) plotted by WHO PS.
(TIF)
Figure S4 Networks obtained from entering the identi-
fied 29 proteins into the Ingenuity Pathway Analysis
system. Highest-scoring (A) and combined highest- and second
highest-scoring (B) networks. Panel A represents a more annotated
version of Figure 4 in the main manuscript material. In panel B,
combining the two networks with the highest scores further adds
IL1-beta, HNF1A, HNF4A, HNF6 (ONECUT1), and CEBPB as
central components (green shading). In panel A, dark blue shapes
and lines = proteins identified as predictors in this study and
interactions between them. Grey shapes and lines = proteins
identified by Ingenuity to generate the network and interactions
between them. Light blue lines = interactions between proteins
identified by Ingenuity to generate the network and the proteins
identified in the study. A Relationship labels: A = Activation; B =
Binding; C = Causes/Leads to; CC = Chemical-Chemical
interaction; CP = Chemical-Protein interaction; E = Expression
(includes metabolism/synthesis for chemicals); EC = Enzyme
Catalysis; I = Inhibition; L = ProteoLysis (includes degradation
for Chemicals); LO = Localization; M = Biochemical Modifi-
cation; MB = Group/complex Membership; P = Phosphoryla-
tion/Dephosphorylation; PD = Protein-DNA binding; PP =
Protein-Protein binding; PR = Protein-RNA binding; RB =
Regulation of Binding; RE = Reaction; RR = RNA-RNA
Binding; T = Transcription; TR = Translocation. Numbers in
brackets = number of observations supporting the interaction. B
Proteins identified in the study: SERPINA1 = alpha-1-antitryp-
sin; SERPINA3 = alpha-1-antichymotrypsin; SERPINC1 =
antithrombin-III; APOA1 = apolipoprotein A-I; APOB =
apolipoprotein B-100; APOC3 = apolipoprotein C-III; C3 =
complement C3; C4A, C4B = complement C4-A; complement
C4-B; C9 = complement component C9; GSN = gelsolin;
HBA2 = hemoglobin alpha; HBB, HBD = hemoglobin beta/
delta; HP = haptoglobin; HPR = haptoglobin-related protein;
HRG = histidine-rich glycoprotein; KLKB1 = plasma kallikrein;
IGKC = Ig kappa chain V-III region Ti; RBP4, Rbp = retinol
binding protein 4; APCS = serum amyloid P-component; TF =
serotransferrin; TTR = transthyretin; ORM1 = alpha-1-acid
glycoprotein 1; A1BG = alpha-1B-glycoprotein; LRG1 =
leucine-rich alpha-2-glycoprotein; ARMC2 = armadillo repeat-
containing protein 2; AHSG = alpha-2-HS-glycoprotein; ITIH4
= inter-alpha-trypsin inhibitor heavy chain H4.
(TIF)
Figure S5 Scatterplots of intensities from Western blots
(densitometry) and MS/MS for 9 selected differentially
expressed proteins. Red triangles = cases; green circles =
controls. APOA1 = apolipoprotein A–I; C3 = complement C3; C4
= complement C4-A; fetuin = alpha-2-HS-glycoprotein; HPT beta
= haptoglobin; ORM1 = alpha-1-acid glycoprotein; serpin A1 =
alpha-1-antitrypsin; serpin A3 = alpha-1-antichymotrypsin.
(TIF)
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selected differentially expressed proteins. 1 mg (0.1 mg for
serpin A1) of depleted human plasma proteins of study samples (6
ILD cases and 6 controls) were separated by SDS-PAGE,
transferred onto PVDF membrane, and detected with Western
blotting. alpha-2-HS-glycoprotein = alpha-2-HS-glycoprotein;
APOA1 = apolipoprotein A-I; C3 beta-chain = complement
C3 beta-chain; C4 beta-chain = complement C4 beta-chain;
HPT beta-chain = haptoglobin beta-chain; orsomucoid-1 =
alpha-1-acid glycoprotein; serpin A1 = alpha-1-antitrypsin; serpin
A3 = alpha-1-antichymotrypsin.
(TIF)
Figure S7 Significance levels from proteins, constituent
peptides, and acute phase pathway intensities, adjusted
for clinical variables. p-values for the proteins are shown by red
stars, p-values for individual peptides are shown by points, and the
distribution of these for each protein is shown by a boxplot. In each
boxplot, the upper and lower sides of the box represent the higher and
lower quartile values (Q3 and Q1), respectively. The black bar in each
box represents the median value. The p-value for the acute phase
pathway is represented by the dashed line; boxplots for proteins in the
acute phase response pathway are shaded. A1AG1 = alpha-1-acid
glycoprotein; A1AT = alpha-1-antitrypsin; A1BG = alpha-1-B-
glycoprotein; A2GL = leucine-rich alpha-2-glycoprotein; AACT =
alpha-1-antichymotrypsin; ANT3 = antithrombin-III; APOA1 =
apolipoprotein A–I; APOB = apolipoprotein B-100; APOC3 =
apolipoprotein C-III; ARMC2 = armadillo repeat-containing protein
2; CO3 = complement C3; CO4 = complement C4-A, complement
C4-B; CO9 = complement component C9; FETUA = alpha-2-HS-
glycoprotein; GELS = gelsolin; HBA = hemoglobin alpha;
HBB,HBD = hemoglobin beta/delta; HPT = haptoglobin; HPTR
= haptoglobin-related protein; HRG = histidine-rich glycoprotein;
ITIH4 = inter-alpha-trypsin inhibitor heavy chain H4; KLKB1 =
plasma kallikrein; KV3 = Ig kappa chain V-III region Ti; RETBP =
retinol binding protein 4; SAMP = serum amyloid P-component;
TRFE = serotransferrin; TTHY = transthyretin.
(TIF)
Table S1 Characteristics of study subjects (NSCLC
patients treated with gefitinib) included in proteomics
analyses.
(DOC)
Table S2 Quality control results of sample preparation
for 181 study samples, by LC-MS/MS measurement
batches.
(DOC)
Table S3 Protein Identification from the selected
peaks.
(DOC)
Table S4 Antibodies used for Western Blot validation.
(DOC)
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